Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001Vertical integration of major ...

Epithelial ovarian cancer is the fourth biggest cause of cancer-related death in women. Over recent decades, improvements have been made in treatment outcome in terms of response rate and survival.

LONDON, UK I, 2024 I GSK plc (LSE/NYSE: GSK) today announced headline results from the FIRST-ENGOT-OV44 phase III trial evaluating Zejula ...

Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001 Vertical integration of major components assures a high-quality, commercially viable futur ...

The results come two months after Merck shared positive results from the phase 3 KEYNOTE-689 trial of Keytruda as a ...

GSK’s FIRST-ENGOT-OV44 phase III clinical trial of Zejula and Jemperl in first line advanced ovarian cancer meets primary endpoint: London Saturday, December 21, 2024, 09:00 Hrs ...

Despite marijuana remaining a Schedule I drug on the federal level, 2024 has been a huge year for marijuana research. As ...

including a preliminary dose-finding combination study of Zejula and Keytruda with metastatic triple-negative breast cancer (TNBC) or recurrent platinum-resistant epithelial ovarian cancer.

Bevacizumab is used in the treatment of multiple cancers including metastatic colorectal cancer, recurrent or metastatic non-squamous non-small cell lung cancer, advanced and/or metastatic renal cell ...

But what if they could prevent the spread of cancer altogether? Well, that’s precisely what OvarianVax, the world’s first ovarian cancer prevention vaccine, strives to do. Researchers at the ...

On Friday (December 20), shares of Aurobindo Pharma Ltd ended at ₹1,240.70, down by ₹14.70, or 1.17% on the BSE.

Merck's strong financial performance in oncology and vaccines drove a 9% sales increase earlier in Q1 of 2024. See why I rate ...